The goal of phase 1 of this clinical research study is to find the highest dose of
DOTAP:Chol-TUSC2 that can be safely given in combination with Tarceva (erlotinib
hydrochloride) to patients with NSCLC.
The goal of phase 2 of this clinical research study is to learn if the combination of
DOTAP:Chol-TUSC2 and erlotinib hydrochloride can help to control NSCLC.
The safety of this drug combination will also be studied in both phases.
DOTAP:Chol-TUSC2 (previously FUS1) is a drug that helps transfer a gene called TUSC2 into
cancer cells. Researchers think that cells without this gene may be involved in the
development of lung cancer tumors. They want to find out if replacing the gene in these cells
may keep the tissue from forming cancer cells.
Erlotinib hydrochloride is designed to block a protein on tumor cells that may control tumor
growth and survival. This may stop tumors from growing.